Cocaine-and amphetamine-regulated transcript is expressed in hypothalamic regions involved in the central control of food intake. Previous data have implicated cocaine-and amphetamine-regulated transcript as an anorectic peptide. We studied the effect of the active fragment of cocaine-and amphetamine-regulated transcript, cocaine-and amphetamine-regulated transcript-(55-102), on feeding when injected into discrete nuclei of the hypothalamus. Cocaine-and amphetamine-regulated transcript-(55-102) (0.04 nmol) elicited a delayed, but significant, increase in feeding in 24-h fasted rats after injection into the ventromedial nucleus (1-2 h, 261 ؎ 60% of control; P < 0.05) and arcuate nucleus (1-2 h, 225 ؎ 38% of control; P < 0.05) of the hypothalamus. Administration of a higher dose of cocaine-and amphetamineregulated transcript-(55-102) (0.2 nmol) elicited a significant increase in feeding after injection into the ventromedial nucleus (1-2 h, 1253 ؎ 179% of control; P < 0.001), arcuate nucleus (1-2 h, 265 ؎ 43% of control; P < 0.05), paraventricular nucleus 
C OCAINE-AND AMPHETAMINE-REGULATED transcript (CART) cDNA was originally isolated from rat brain by PCR differential screening of transcripts up-regulated after the administration of cocaine or amphetamine (1) . CART and its translated peptide are found throughout the central nervous system and peripheral tissues (1) (2) (3) (4) (5) . CART is one of the most abundant mRNAs in the hypothalamus, highly expressed in the arcuate nucleus (ARC), paraventricular nucleus (PVN), dorsomedial nucleus (DMN) and ventromedial nucleus (VMN) (1, 6) . These nuclei have established roles in the regulation of feeding.
CART has been implicated in the control of feeding behavior. CART mRNA and peptide are colocalized with the anorectic peptide ␣MSH in the ARC and with the orexigenic peptide melanin-concentrating hormone in the lateral hypothalamic area (LHA) (7) (8) (9) . Nerve terminals immunoreactive for the orexigenic peptide NPY are closely apposed with CART peptide-containing cell bodies in the PVN, ARC, LHA, and DMN (8, 10) . Intracerebroventricular (icv) injection of the active fragment of CART, CART(55-102), has been shown to activate the immediate early gene c-fos in the PVN, DMN, ARC, and supraoptic nucleus (SON) of the hypothalamus (11) .
Additional data suggested a role for CART as an endogenous inhibitor of food intake. Hypothalamic CART peptide and mRNA levels are decreased in fasted Wistar rats, obese leptin-deficient ob/ob mice, and obese leptin receptor-defective Zucker rats (12) . Intracerebroventricular administration of a polyclonal CART antiserum significantly increased nocturnal feeding in satiated rats (12, 13) . Several groups, including our own, reported inhibition of food intake after icv injection of CART(55-102) (11) (12) (13) (14) . Kristensen et al. noted that icv administration of CART(55-102) caused movementassociated tremor, but reported no changes in spontaneous locomotor activity levels when monitored in isolated activity test chambers for 1 h postinjection (12) .
To further characterize the areas of the hypothalamus in which CART influences feeding, CART(55-102) was injected into discrete hypothalamic nuclei. The nuclei into which CART(55-102) was injected in this study contain both CART mRNA and peptide and have been implicated in the regulation of food intake and energy expenditure. Food intake and behavioral effects were monitored after the injection of peptide. As these studies elicited unexpected results, feeding and behavioral effects of icv CART(55-102) were reexamined.
Abbreviations: AHA, Anterior hypothalamic area; ARC, arcuate nucleus; CART, cocaine-and amphetamine-regulated transcript; DMN, dorsomedial nucleus; icv, intracerebroventricular; LHA, lateral hypothalamic area; MPO, medial preoptic area; PVN, paraventricular nucleus; SON, supraoptic nucleus; VMN, ventromedial nucleus.
Materials and Methods Animals
Male Wistar rats (250 -350 g) were maintained in individual cages under controlled temperature (21-23 C) and light (12 h of light, 12 h of darkness; lights on at 0700 h) conditions with ad libitum access to food (RM1 diet, SDS UK Ltd., London, UK) and water. All animal procedures undertaken were approved by the British Home Office Animals Scientific Procedures Act 1986 (Project License 90/1077).
Intranuclear and icv cannulation
Animal surgical procedures and handling were carried out as previously described (15) . Animals were anesthetized by ip injection of a mixture of Ketalar (ketamine HCl, 60 mg/kg; Parke-Davis, Pontypool, UK) and Rompun (xylazine, 12 mg/kg; Bayer Corp. UK Ltd., Bury St. Edmunds, UK) and placed in a Kopf stereotaxic frame. For intranuclear cannulation, animals were implanted with permanent 26-gauge stainless steel guide cannulae (Plastics One, Inc., Roanoke, VA) projecting into the medial preoptic area (MPO), SON, anterior hypothalamic area (AHA), PVN, VMN, DMN, ARC, and LHA of the hypothalamus, according to coordinates of Paxinos and Watson (16) ( Table 1) . For icv cannulation, permanent 22-gauge stainless steel guide cannulae were stereotactically placed 0.8 mm posterior to the bregma on the midsagittal line and implanted 6.5 mm below the outer surface of the skull, into the third cerebral ventricle [coordinates calculated using atlas of Paxinos and Watson (16) ]. All compounds were dissolved in 0.9% saline, and each study involved an injection of peptide or saline in a volume of 1 l (for intranuclear studies) or 5 l (for icv studies) over 1 min. Substances were administered by a 31-gauge (for intranuclear studies) or a 27-gauge (for icv studies) stainless steel injector placed in and projecting 1 mm below the tip of the cannulas. All substances were administered in the early light phase (0900 -1000 h). Correct intranuclear cannula placement was confirmed histologically at the end of the study period. After injection of 1 l black ink, animals were decapitated, and brains were removed, immediately frozen in liquid nitrogen, and stored at Ϫ70 C. Brains were sliced on a cryostat (Bright, Huntingdon, UK) into 15 m coronal sections and stained with cresyl violet. Correct icv cannula placement was confirmed by a positive dipsogenic response to angiotensin II (150 ng/rat). Only those animals with correct placement of cannulas were included in the data analysis.
Study 1: effect of intranuclear injection of CART(55-102) on food intake in the 24 h fasted rat
This study was of a random cross-over design, whereby 24-h fasted rats (n ϭ 9 -13/group) received saline, 0.04 nmol (0.2 g) CART(55-102), and 0.2 nmol (1 g) CART(55-102) (Peptide Institute, Osaka, Japan). After injection, animals were returned to their home cages, which contained a preweighed amount of chow. At 1, 2, 4, 8, and 24 h postinjection, food remaining in the cage dispenser was weighed using a GW 600 balance (ATP Instrumentations, Ltd., Ashby-De-la-Zouche, UK) recording to the nearest 0.1g.
Study 2: effect of intranuclear injection of CART(55-102) on food intake in the satiated rat
After the observed increase in food intake in 24-h fasted rats following injection of CART(55-102) into selective hypothalamic nuclei, satiated rats cannulated into the DMN were injected with either saline or 0.2 nmol CART(55-102) (n ϭ 10 -12/group), and their food intake monitored. After injection, animals were returned to their home cages containing a preweighed amount of chow, and their food intake was measured at 1, 2, 4, 8, and 24 h post injection as described above.
Study 3: effect of icv injection of CART(55-102) on food intake and behavior in the 24-h fasted and satiated rats
Intracerebroventricularly cannulated, satiated and 24-h fasted rats (n ϭ 9 -10/group) were injected in the early light phase with saline or 0.2 nmol (1 g) or 0.4 nmol (2 g) CART(55-102). Animals were then immediately returned to their home cages, which contained a preweighed amount of chow. Food intake of the satiated animals was determined at 1, 2, 4, 8, and 24 h postinjection as detailed above. Twentyfour-hour fasted rats were observed for behavioral analysis. The rats were observed continuously for 4 h postinjection by observers blinded to the experimental treatment. Behavior was classified into nine different categories: feeding, drinking, grooming, burrowing, rearing, locomotion, sleeping, head down, and flattened body posture/movementassociated tremor (Table 2) , adapted from Fray et al. (17) . Each rat was observed for 10 sec every 6 min during the test session. This 10-sec period was further divided into three parts, and the behavior of the rat in each section of the time period was scored. So as not to disturb the behavioral analysis, food intake was only measured at 4, 8, and 24 h postinjection.
Study 4: effect of intranuclear injection of CART(55-102) on behavior in the satiated rat
To determine whether intranuclear injection of CART(55-102) elicited abnormal locomotor responses, the behavioral responses of animals cannulated into the ARC were monitored after CART(55-102) administration. Satiated rats (n ϭ 8/group) were injected with saline or 0.04, 0.2, or 0.4 nmol CART(55-102) and immediately returned to their home cages. The behaviors of these animals were then observed continuously for 4 h postinjection as detailed above.
Statistical analysis
Intranuclear food intake data for 24 h fasted rats are expressed as the mean Ϯ sem percentage of the control value. Statistical analysis for both doses of peptide at each nucleus and time point was carried out by paired t test. DMN food intake data for satiated rats and icv food intake data are expressed as the mean Ϯ sem. Data at each time point were compared by ANOVA, followed by a post-hoc least significant difference analysis (Systat, Evanston, IL). Behavioral data are expressed as the median number of occurrences of behavior (interquartile ranges are expressed in square brackets). Comparisons between groups were made by Mann-Whitney U test. f P Ͻ 0.05 was considered significant.
Results

Study 1: effect of intranuclear injection of CART(55-102) on food intake in the 24 h fasted rat
The data below are expressed as the mean Ϯ sem percentage of the saline control. Mean saline values for each time 
MPO.
There was no significant alteration in feeding after the administration of 0.04 nmol CART(55-102) at any time point measured (Fig. 1A) . After the injection of 0.2 nmol CART(55-102) a decrease in food intake was seen only at 1 h after injection (56 Ϯ 15% of control; P Ͻ 0.05).
SON. There was no significant alteration in feeding after the administration of 0.04 nmol CART(55-102) at any time point measured (Fig. 1B) . After the injection of 0.2 nmol CART(55-102), an increase in feeding was observed at 2-4 h postinjection (212 Ϯ 34%; P Ͻ 0.05).
AHA. There was no significant alteration in feeding after the administration of 0.04 nmol CART(55-102) at any time point measured (Fig. 1C) . Administration of 0.2 nmol CART(55-102) increased feeding at 2-4 h postinjection (252 Ϯ 42%; P Ͻ 0.01).
PVN. Similar to injection into the SON and AHA, there was no significant alteration in feeding after the administration of 0.04 nmol CART(55-102) at any time point measured ( DMN. Rats cannulated into the DMN showed no significant alteration in feeding after the administration of 0.04 nmol CART(55-102) (Fig. 1F) . Administration of 0.2 nmol CART(55-102) significantly increased feeding in both the 1-2 and 2-4 h postinjection periods (1-2 h, 240 Ϯ 35%; 2-4 h, 368 Ϯ 29%; both P Ͻ 0.001). A slight reduction in feeding was seen at 8 -24 h postinjection (79 Ϯ 6%; P Ͻ 0.05).
ARC. Both 0.04 and 0.2 nmol CART(55-102) caused a significant increase in feeding at 1-2 h postinjection when administered into the ARC (0.04 nmol, 225 Ϯ 38%; 0.2 nmol, 265 Ϯ 43%; both P Ͻ 0.05; Fig. 1G ). This increase was maintained throughout the 2-to 4-h postinjection period following 0.2 nmol CART(55-102), but returned to control levels after 0.04 nmol CART(55-102) (0.2 nmol, 209 Ϯ 18%; P Ͻ 0.01). A subsequent decrease in feeding with respect to control levels was observed after the injection of 0.2 nmol CART(55-102) during the 4-to 8-h postinjection period (61 Ϯ 11%; P Ͻ 0.05).
LHA. Administration of 0.04 nmol CART(55-102) into the LHA caused a decrease in feeding only at 4 -8 h postinjection (68 Ϯ 10%; P Ͻ 0.05; Fig. 1H ). In contrast, injection of 0.2 nmol CART(55-102) elicited a significant increase in feeding at 2-4 h postinjection (280 Ϯ 34%; P Ͻ 0.001), whereas a reduction in feeding was measured at 8 -24 h postinjection (83 Ϯ 5%; P Ͻ 0.001). 
Study 2: effect of intranuclear injection of CART(55-102) on food intake in the satiated rat
The data below are expressed as the mean Ϯ sem percentage of the saline control value. Mean saline values for each time point are: 0 -1 h, 2.3 Ϯ 0.2 g; 1-2 h, 1.3 Ϯ 0.3 g; 2-4 h, 1.5 Ϯ 0.3 g; 4 -8 h, 5.8 Ϯ 0.5 g; and 8 -24 h, 18.2 Ϯ 0.7 g. CART(55-102) significantly increased feeding after injection into the DMN of satiated rats (Fig. 2) . Administration of 0.2 nmol CART(55-102) increased feeding by approximately 200% of the saline control value (191 Ϯ 21% of saline control; P Ͻ 0.001) at 1-2 h postinjection. Food intake during the 2-4 h postinjection period was still significantly elevated above the control level (160 Ϯ 24% of control; P Ͻ 0.05). A subsequent decrease in feeding with respect to control levels was observed during the 4-to 8-h postinjection period (64 Ϯ 11% of control; P Ͻ 0.05). Food intake at 8 -24 h postinjection was not significantly different from control levels (Fig. 2) .
Study 3: effect of icv injection of CART(55-102) on food intake and behavior in the 24 h fasted and satiated rat
The data below are expressed as the mean Ϯ sem percentage of the saline control value. Mean 24 h fasted saline values for each time point are: 0 -4 h, 6.0 Ϯ 0.5 g; 4 -8 h, 4.8 Ϯ 1.1 g; and 8 -24 h, 15.2 Ϯ 1.7 g. CART(55-102) significantly inhibited feeding when administered icv into 24 h fasted rats (Fig.  3A) . CART(55-102) (0.2 nmol) decreased feeding to 50 Ϯ 15% of the control value (P Ͻ 0.01), and 0.4 nmol CART(55-102) reduced feeding to 33 Ϯ 13% of the control value (P Ͻ 0.001) in the 4 h after injection (Fig. 3A) . In the higher dose group food intake was still inhibited during the 4-to 8-h period (66 Ϯ 13% control; P Ͻ 0.001), but returned to control levels at the later time point (Fig. 3A) .
The data below are expressed as the mean Ϯ sem percentage of the saline control value. Mean satiated saline values for each time point are: 0 -4 h, 1.3 Ϯ 0.4 g; 4 -8 h, 2.7 Ϯ 0.5 g; and 8 -24 h, 17.1 Ϯ 1.2 g. A greater effect was observed after icv administration of CART(55-102) into satiated rats (Fig.  3B) . CART(55-102) (0.2 nmol) decreased feeding to 41 Ϯ 18% of the control value (P Ͻ 0.05), and 0.4 nmol CART(55-102) markedly reduced feeding to 9 Ϯ 7% of the control value (P Ͻ 0.01) in the 4-h postinjection period (Fig. 3B) . Food intake was still significantly inhibited in the higher dose group during the 4-to 8-h (14 Ϯ 9% of control; P Ͻ 0.001) and 8-to 24-h (52 Ϯ 10% of control; P Ͻ 0.01) postinjection periods (Fig. 3B) .
Twenty-four-hour fasted, saline-treated rats exhibited a common behavioral satiety sequence of grooming and sleeping after an initial period of feeding, whereas 24-h fasted CART(55-102)-treated rats displayed an abnormal behavioral pattern (Table 3 , A-C) (18) . Rats treated with CART(55-102) exhibited a significant reduction in feeding episodes, with no increase in grooming or sleeping during the first hour postinjection compared with saline-treated animals ( Table 3A) . Fifty and 78% of rats injected with 0.2 and 0.4 nmol CART(55-102), respectively, adopted a flattened body posture and exhibited a movement-associated tremor throughout the 4-h observational period compared with saline-injected controls (Table 3 , A-C). No saline-treated animals demonstrated this behavior. Rats treated with CART(55-102) (0.2 or 0.4 nmol) that did not exhibit this abnormal body posture and associated tremor showed a significant increase in head down and burrowing behavior compared with saline controls (Table 3 , A-C).
Study 4: effect of intranuclear injection of CART(55-102) on behavior in the satiated rat
No flattened body posture or movement-associated tremor were observed after administration of either CART(55-102) or saline into the ARC (Table 4 , A-C). A dose-dependent increase in feeding episodes was observed after CART(55-102) administration, although it was not significant from control levels until 1-2 h postinjection (Table  4B) . This increase in feeding episodes was associated with increasing burrowing and a subsequent decrease in sleeping episodes, both of which were significantly altered from saline-injected control animals ( Table 4 , A-C).
Discussion
We have shown that injection of CART(55-102) into discrete hypothalamic nuclei of 24 h fasted rats resulted in a significant increase in feeding. Injection of 0.2 nmol CART(55-102) into the SON, AHA, PVN, VMN, DMN, ARC, or LHA significantly increased feeding compared to salineinjected animals. The feeding response to CART(55-102) was more marked after injection into the VMN, DMN, ARC, and LHA, suggesting that these nuclei are more sensitive to CART. Administration of CART(55-102) into the DMN of satiated rats elicited an increase in food intake that was similar in both magnitude and time course to the response in 24-h fasted rats. Interestingly, the increase in feeding observed after intranuclear injection of CART(55-102) in both 24-h fasted and satiated rats was not apparent until 1 or 2 h after injection. This delay contrasts with the immediate action of other orexigenic peptides, such as galanin and melanin-concentrating hormone (17, 19) . A significant reduction in feeding between 4 -24 h postinjection was observed after administration into the DMN, ARC, and LHA. This may be a compensatory decrease after the stimulation of feeding at earlier time points. A late direct anorectic effect of the peptide is also possible. An early decrease in feeding was only seen after injection into the MPO.
It could be argued that the effects reported here lack anatomical specificity due to diffusion. Although very small doses of peptide were administered in the intranuclear studies, the possibility of diffusion beyond the area of injection must be considered. An increase in food intake was seen after injection of CART(55-102) into the SON, an area that has not previously been implicated in the control of feeding. It could be hypothesized that this increase was due to diffusion to the DMN, VMN, or ARC, nuclei that have been shown in this study to elicit a significant increase in feeding after CART(55-102) administration. If this were the case, however, then an increase in feeding would have been expected after injection into the MPO, which is anatomically nearer to the highly responsive nuclei than the SON. We have shown that injection of CART(55-102) into the MPO does not increase feeding. This suggests that the response after injection into the SON is specific and is unlikely to be due to diffusion. Our data therefore suggest that for the doses chosen in this study the diffusion effect from one nucleus to another is small. Intracerebroventricular injection of CART(55-102) into both 24-h fasted and satiated rats resulted in a significant and sustained reduction in feeding, comparable to previous findings (12) . We also noted that icv administration of CART(55-102) was associated with marked abnormalities in behavior. After icv injection of 0.4 nmol CART(55-102), nearly 80% of animals adopted a flattened body posture and exhibited movement-associated tremor, both of which were evident as early as 10 min postinjection. None of the animals treated with CART(55-102) showed an increase in grooming or sleeping episodes, behaviors that would be expected after the administration of an anorectic peptide (18) . After an initial period of feeding, the saline-treated rats exhibited the expected behavioral satiety sequence of grooming and sleeping (18) . Movement-associated tremors have been documented in previous studies after icv administration of CART(55-102), although in the studies performed it was not thought to alter the ability to feed (11, 12) . The presence of motor abnormalities and tremor in CART(55-102)-treated animals could suggest that the inhibition in feeding seen after icv administration is an adverse, rather than a true anorectic, effect. Injection of equivalent doses of CART(55-102) into the ARC increased feeding episodes, but was not associated with any of these behavioral abnormalities.
CART(55-102) has previously been proposed as an anorectic neuropeptide. Kristensen et al. (12) have shown a significant reduction in ARC and DMN CART mRNA expression after a 48-h fast. However, studies within our laboratory have shown an increase in CART immunoreactivity in discrete regions of the hypothalamus under similar conditions (20) . Interestingly, it has recently been reported that CART knockout mice show a slight, but consistent, reduction in body weight and fat mass, although these trends did not reach significance (21) . It is possible, therefore, that CART is differentially regulated within the hypothalamus. Recent studies have shown both amplificatory and inhibitory effects after application of CART peptide to ␥-aminobutyric acidergic populations in the PVN (22) . These different responses could represent two types of CART appetite circuits within the hypothalamus, one orexigenic and the other anorectic. This theory may help to explain why a delayed increase in feeding after intranuclear CART(55-102) injection is seen in both the fasted and satiated states. Alternatively, the injected CART(55-102) might activate an inhibitory autoreceptor. Such a mechanism has been recently postulated for the melanocortin-3 receptor effect on the melanocortin feeding system (23) .
Our data indicate that the effects of CART on feeding regulation are complex, but suggest a novel role for CART peptide as an orexigenic neuropeptide.
